This Amendment expands the scope of Northstrive Biosciences’ license rights to all uses in animal health ... to entry within the animal health pharmaceutical sector. Northstrive Biosciences ...

Telomir Pharmaceuticals (NASDAQ:TELO) announced on Wednesday, preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly ...

"These results not only confirm in-vitro observations in aggressive, androgen-independent human prostate cancer cells but also represent a game-changing discovery in animal models. We are seeing a ...

This growth is believed to be a consequence of rising innovations surrounding companion animal pharmaceuticals, increasing millennial pet adoption rates, growing livestock populations and ...

This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...